ZA200809016B - 4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders - Google Patents

4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders

Info

Publication number
ZA200809016B
ZA200809016B ZA200809016A ZA200809016A ZA200809016B ZA 200809016 B ZA200809016 B ZA 200809016B ZA 200809016 A ZA200809016 A ZA 200809016A ZA 200809016 A ZA200809016 A ZA 200809016A ZA 200809016 B ZA200809016 B ZA 200809016B
Authority
ZA
South Africa
Prior art keywords
pteridiness
triazolo
dihydro
treatment
protein kinase
Prior art date
Application number
ZA200809016A
Inventor
Jean-Damien Charrier
David Kay
Ronald Knegtel
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ZA200809016B publication Critical patent/ZA200809016B/en

Links

ZA200809016A 2006-04-12 2008-10-21 4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders ZA200809016B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79132706P 2006-04-12 2006-04-12

Publications (1)

Publication Number Publication Date
ZA200809016B true ZA200809016B (en) 2010-04-28

Family

ID=40880922

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200809016A ZA200809016B (en) 2006-04-12 2008-10-21 4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders

Country Status (2)

Country Link
CN (1) CN101484457B (en)
ZA (1) ZA200809016B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011311960A1 (en) * 2010-10-08 2014-04-10 Elan Pharmaceuticals, Inc. Inhibitors of polo-like kinase
CN110511226B (en) * 2019-09-06 2021-07-09 西南交通大学 Compound or salt or solvate thereof, application thereof and pharmaceutical composition
CN111808110B (en) * 2020-07-17 2022-07-26 成都师范学院 Pyrimidine-piperazine-1, 2, 4-triazole derivative and preparation method and application thereof
WO2022166725A1 (en) * 2021-02-08 2022-08-11 南京明德新药研发有限公司 5,6-dihydrothieno[3,4-h]quinazoline compound
WO2024032558A1 (en) * 2022-08-08 2024-02-15 南京明德新药研发有限公司 Salt form and crystal form of 5,6-dihydrothieno[3,4-h]quinazoline compound and preparation method therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
DE102004029784A1 (en) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments

Also Published As

Publication number Publication date
CN101484457B (en) 2014-09-03
CN101484457A (en) 2009-07-15

Similar Documents

Publication Publication Date Title
HK1134486A1 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4,3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders plk1 45--[124][43- f]
WO2007111904A3 (en) C-met protein kinase inhibitors for the treatment of proliferative disorders
ZA200802998B (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL190061A0 (en) 5-amino-4-hydroxy-7-(imidazo[1,2-a]pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
IL185016A0 (en) Compounds for the treatment of proliferative disorders
HK1143154A1 (en) Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors b[23-d]
EP1945222A4 (en) Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
EP2063897A4 (en) Kinase inhibitors useful for the treatment of proliferative diseases
EP2063896A4 (en) Kinase inhibitors useful for the treatment of proliferative diseases
SI1893612T1 (en) PYRROLO ?á2, 3-B?åPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
IL189980A0 (en) Novel imidazo [4,5-b]pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
EP1804794A4 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer s disease
EP1796467A4 (en) Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
HK1122808A1 (en) Preparation and use of tetrahydropyrrolo [3, 2-c]t pyridin-4-one derivatives for treatment of obesitty, psychiatric and neurological disorders
PT2073811E (en) Kinase inhibitors useful for the treatment of myeloproliferative diseases and other proliferative diseases
IL195238A0 (en) Pyrazolo [1,5-a]pyrimidines as cdk inhibitors
EP2142544B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
EP2142543B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
EP1789034A4 (en) Compounds with diphenoyl -structure for the treatment of immune diseases
HK1129888A1 (en) 6,7,8,9-tetrahydro-5h-pyrimido[4,5-d]azepin-4-yl]-amine derivatives as modulators of trpv1 for the treatment of pain trpv1 6789--5h-[45-d]-4- ]-
AU2003242860A8 (en) 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders